FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200226786> ?p ?o ?g. }

• W4200226786 endingPage "577790" @default.
• W4200226786 startingPage "577790" @default.
• W4200226786 abstract "Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disease of the central nervous system, which mainly involves the optic nerve and spinal cord. Frequent relapse can accumulate the degree of disability. At present, the main treatment options are immunosuppressants and blood purification. The first-line immunosuppressants for NMOSD are mainly rituximab (RTX), mycophenolate mofetil (MMF) and azathioprine (AZA). Therefore, we designed this systematic review and meta-analysis to evaluate the safety and effect of the above three drugs in the treatment of NMOSD patients.The following Medical Subject Heading (MeSH) and related entry terms are used to search English literature in PubMed, MEDLINE and CENTRAL databases, respectively. MeSH include: Neuromyelitis optic and Rituximab or Azathioprine or Mycophenolate Mofetil; entry terms include: NMO Spectrum Disorder, NMO Spectrum Disorders, Neuromyelitis Optica (NMO) Spectrum Disorder, Neuromyelitis Optica Spectrum Disorders, Devic Neuromyelitis Optica, Neuromyelitis Optica, Devic, Devic's Disease, Devic Syndrome, Devic's Neuromyelitis Optica, Neuromyelitis Optica (NMO) Spectrum Disorders, CD20 Antibody, Rituximab CD20 Antibody, Mabthera, IDEC-C2B8 Antibody, GP2013, Rituxan, Mycophenolate Mofetil, Mofetil, Mycophenolate, Mycophenolic Acid, Morpholinoethyl Ester, Cellcept, Mycophenolate Sodium, Myfortic, Mycophenolate Mofetil Hydrochloride, Mofetil Hydrochloride, Mycophenolate, RS 61443, RS-61443, RS61443, azathioprine sodium, azathioprine sulfate (note: literature retrieval operators AND OR NOT are used to link MeSH with Entry Terms.) The literature search found a total of 3058 articles about rituximab, mycophenolate mofetil and azathioprine in the treatment of NMOSD, 63 of which were included in this study after a series of screening.930,933,732 patients with NMOSD were enrolled, who had been treated with MMF, AZA and RTX, respectively. The pooled standardized mean difference (SMD) of EDSS before and after RTX treated was -0.58 (95%CI: -0.72, -0.44) (I2 = 0%, p = 0.477), before and after MMF treated was -0.47 (95%CI: -0.73, -0.21) (I2 = 85.6%, p<0.001), before and after AZA treated was -0.41 (95%CI: -0.60, -0.23) (I2 = 65.4%, p<0.001). there was no significant difference in the effect of the three drugs on reducing EDSS scores (RTX vs MMF, p = 0.522; RTX vs AZA, p = 0.214; MMF vs AZA, p = 0.732). The pooled standardized mean difference (SMD) of ARR before and after RTX treated was -1.45 (95%CI: -1.72, -1.18) (I2 = 72.4%, p<0.001), before and after MMF treated was -1.14 (95%CI: -1.31, -0.97) (I2 = 54.5%, p<0.001), before and after AZA treated was -1.11 (95%CI: -1.39, -0.83) (I2 = 83.4%, p<0.001). RTX significantly reduced ARR compared with the other two drugs (RTX vs MMF, p = 0.039; RTX vs AZA, p = 0.049; MMF vs AZA, p = 0.436).The results of this systematic review and meta-analysis showed that the treatment of NMOSD patients with RTX, MMF and AZA is associated with decreased number of relapses and disability improvement as well, and there was no significant difference in the effect of the three drugs on reducing EDSS scores, but RTX significantly reduced ARR compared with the other two drugs." @default.
• W4200226786 created "2021-12-31" @default.
• W4200226786 creator A5037516021 @default.
• W4200226786 creator A5046471246 @default.
• W4200226786 creator A5048186002 @default.
• W4200226786 creator A5055131613 @default.
• W4200226786 creator A5090316229 @default.
• W4200226786 date "2022-02-01" @default.
• W4200226786 modified "2023-10-04" @default.
• W4200226786 title "Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis" @default.
• W4200226786 cites W1522374426 @default.
• W4200226786 cites W1537972189 @default.
• W4200226786 cites W1823172479 @default.
• W4200226786 cites W1972241906 @default.
• W4200226786 cites W1976554229 @default.
• W4200226786 cites W2005486905 @default.
• W4200226786 cites W2009114633 @default.
• W4200226786 cites W2014893669 @default.
• W4200226786 cites W2021279859 @default.
• W4200226786 cites W2023686387 @default.
• W4200226786 cites W2029012161 @default.
• W4200226786 cites W2050098695 @default.
• W4200226786 cites W2057654369 @default.
• W4200226786 cites W2067927161 @default.
• W4200226786 cites W2074604840 @default.
• W4200226786 cites W2082237468 @default.
• W4200226786 cites W2087529564 @default.
• W4200226786 cites W2089363506 @default.
• W4200226786 cites W2092102896 @default.
• W4200226786 cites W2095027842 @default.
• W4200226786 cites W2106308432 @default.
• W4200226786 cites W2114414511 @default.
• W4200226786 cites W2129229339 @default.
• W4200226786 cites W2130342500 @default.
• W4200226786 cites W2136132690 @default.
• W4200226786 cites W2142340239 @default.
• W4200226786 cites W2155049452 @default.
• W4200226786 cites W2162364743 @default.
• W4200226786 cites W2172110489 @default.
• W4200226786 cites W2172149695 @default.
• W4200226786 cites W217860419 @default.
• W4200226786 cites W2185400242 @default.
• W4200226786 cites W2242473891 @default.
• W4200226786 cites W2285134363 @default.
• W4200226786 cites W2296419904 @default.
• W4200226786 cites W2330155556 @default.
• W4200226786 cites W2418688327 @default.
• W4200226786 cites W2444189513 @default.
• W4200226786 cites W2522644963 @default.
• W4200226786 cites W2524675862 @default.
• W4200226786 cites W2540565392 @default.
• W4200226786 cites W2554337911 @default.
• W4200226786 cites W2561708624 @default.
• W4200226786 cites W2568116806 @default.
• W4200226786 cites W2571818105 @default.
• W4200226786 cites W2598687492 @default.
• W4200226786 cites W2621138762 @default.
• W4200226786 cites W2625404774 @default.
• W4200226786 cites W2747029006 @default.
• W4200226786 cites W2778216211 @default.
• W4200226786 cites W2790223348 @default.
• W4200226786 cites W2791305328 @default.
• W4200226786 cites W2791654338 @default.
• W4200226786 cites W2801139582 @default.
• W4200226786 cites W2907468245 @default.
• W4200226786 cites W2908825776 @default.
• W4200226786 cites W2932668297 @default.
• W4200226786 cites W2939976904 @default.
• W4200226786 cites W2946292274 @default.
• W4200226786 cites W2975954377 @default.
• W4200226786 cites W2989102128 @default.
• W4200226786 cites W2989992495 @default.
• W4200226786 cites W2990369603 @default.
• W4200226786 cites W3000029321 @default.
• W4200226786 cites W3012054652 @default.
• W4200226786 cites W3012376934 @default.
• W4200226786 cites W3023041164 @default.
• W4200226786 cites W3046296373 @default.
• W4200226786 cites W3081746831 @default.
• W4200226786 cites W3107025010 @default.
• W4200226786 cites W3137234182 @default.
• W4200226786 doi "https://doi.org/10.1016/j.jneuroim.2021.577790" @default.
• W4200226786 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34959021" @default.
• W4200226786 hasPublicationYear "2022" @default.
• W4200226786 type Work @default.
• W4200226786 citedByCount "3" @default.
• W4200226786 countsByYear W42002267862022 @default.
• W4200226786 countsByYear W42002267862023 @default.
• W4200226786 crossrefType "journal-article" @default.
• W4200226786 hasAuthorship W4200226786A5037516021 @default.
• W4200226786 hasAuthorship W4200226786A5046471246 @default.
• W4200226786 hasAuthorship W4200226786A5048186002 @default.
• W4200226786 hasAuthorship W4200226786A5055131613 @default.
• W4200226786 hasAuthorship W4200226786A5090316229 @default.
• W4200226786 hasConcept C118552586 @default.
• W4200226786 hasConcept C126322002 @default.
• W4200226786 hasConcept C159654299 @default.
• W4200226786 hasConcept C16005928 @default.

• next